Global pharmacovigilance market is anticipated to witness double digit CAGR during the forecast period owing to the increasing drug consumption and drug developments around the globe. Growing prevalence of chronic diseases such as oncology, diabetes, and others has created the need for advanced and more effective pharmaceutical drugs. Keeping in view the chances of Adverse Drug Reactions (ADR) and drug toxicity, healthcare companies are continuously incorporating pharmacovigilance services. Moreover, numerous consumer health protection acts across various regions are further propelling the growth of this market.

Pharmacovigilance is concerned with identifying the hazards associated with pharmaceutical products and minimizing the risk of any harm that may come to patients. The service helps in finding the new safety concerns and evaluating the already known risks. It also helps in keeping a watch on the benefit risk balance of a drug. Any change in the benefit risk ratio will alter the safety profile of the drug.

Global pharmacovigilance market can be segmented based on clinical trial phase, method, service provider, end-user and region. Based on service provider, the market is categorized into in-house and contract outsourcing. Among them, the contract outsourcing service provider dominated the market in 2020 and is expected to dominate the market during the forecast period owing to the fact that it eliminates the risk of business overhead costs and is thus, being increasingly adopted by healthcare companies

Regionally, Asia-Pacific dominates the market and is expected to undergo highest CAGR until 2026 owing to stringent healthcare regulations across the region. The region has also a large patient pool, which is leading to increasing number of clinical trials. Also, countries such as India and China have large clinical research spaces and offer attractive opportunities to healthcare companies.

Major companies operating in global pharmacovigilance market include IBM Corporation, Accenture Plc, Linical Accelovance, Cognizant Technology Solutions Corporation, Laboratory Corporation of America Holdings, ArisGlobal LLC, ICON plc, Capgemini SE, Parexel International Corporation, Wipro Ltd, United BioSource Corporation, BioClinica Inc., TAKE Solutions Ltd., ITClinical, Foresight Group International AG and others. The companies are focusing on research and development activities to offer better pharmacovigilance services and increase their global market share.

Years considered for this report:

Historical Years: 2016-2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022–2026

Objective of the Study:

  • To analyze and forecast the market size of global pharmacovigilance market.
  • To forecast global pharmacovigilance market based on clinical trial phase, method, service provider, end-user, company and regional distribution.
  • To identify drivers and challenges for global pharmacovigilance market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global pharmacovigilance market.
  • To identify and analyze the profile of leading players operating in the global pharmacovigilance market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of service providers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the service providers which could not be identified due to the limitations of secondary research.

TechSci Research calculated global pharmacovigilance market size using a bottom-up approach, where data for various end user industries and its application across various product types was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • Pharmacovigilance service providers, pharmaceutical companies and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to pharmacovigilance
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as pharmacovigilance companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global pharmacovigilance market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Pharmacovigilance Market, By Clinical Trial Phase:
    • Pre-Clinical
    • Phase 1
    • Phase 2
    • Phase 3
    • Phase 4
  • Global Pharmacovigilance Market, By Method:
    • Spontaneous Reporting
    • Intensified ADR Reporting
    • Targeted Spontaneous Reporting
    • Cohort Event Monitoring
    • EHR Mining
  • Global Pharmacovigilance Market, By Service Provider:
    • In-House
    • Contract Outsourcing
  • Global Pharmacovigilance Market, By Process Flow :
    • Case Data Management
    • Signal Detection
    • Risk Management System
  • Global Pharmacovigilance Market, By Therapeutic Area
    • Oncology
    • Neurology
    • Cardiology
    • Others
  • Global Pharmacovigilance Market, By End-User:
    • Pharmaceutical & Biotechnology Companies
    • Medical Device Manufacturers
    • Others
  • Global Pharmacovigilance Market, By Region:
    • Asia-Pacific
      • China
      • Japan
      • India 
      • South Korea
      • Australia
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • North America
      • United States
      • Mexico
      • Canada
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global pharmacovigilance market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.
It is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com  

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Pharmacovigilance Market

4.    Executive Summary

5.    Voice of Customer

6.    Global Pharmacovigilance Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Clinical Trial Phase (Pre-Clinical, Phase 1, Phase 2, Phase 3, and Phase 4)

6.2.2.     By Method (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining)

6.2.3.     By Service Provider (In-House, Contract Outsourcing)

6.2.4.     By End-User (Hospitals, Research Organizations, Industries)

6.2.5.     By Company (2019)

6.2.6.     By Region

6.3.  Market Attractiveness Index

7.    Asia-Pacific Pharmacovigilance Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Clinical Trial Phase

7.2.2.     By Method

7.2.3.     By Service Provider

7.2.4.     By End-User

7.2.5.     By Country

7.3.  Market Attractiveness Index

7.4.  Asia-Pacific: Country Analysis

7.4.1.     China Pharmacovigilance Market Outlook

7.4.1.1.         Market Size & Forecast

7.4.1.1.1.             By Value

7.4.1.2.         Market Share & Forecast

7.4.1.2.1.             By Clinical Trial Phase

7.4.1.2.2.             By Method

7.4.1.2.3.             By Service Provider

7.4.1.2.4.             By End-User

7.4.2.     India Pharmacovigilance Market Outlook

7.4.2.1.         Market Size & Forecast

7.4.2.1.1.             By Value

7.4.2.2.         Market Share & Forecast

7.4.2.2.1.             By Clinical Trial Phase

7.4.2.2.2.             By Method

7.4.2.2.3.             By Service Provider

7.4.2.2.4.             By End-User

7.4.3.     Japan Pharmacovigilance Market Outlook

7.4.3.1.         Market Size & Forecast

7.4.3.1.1.             By Value

7.4.3.2.         Market Share & Forecast

7.4.3.2.1.             By Clinical Trial Phase

7.4.3.2.2.             By Method

7.4.3.2.3.             By Service Provider

7.4.3.2.4.             By End-User

7.4.4.     South Korea Pharmacovigilance Market Outlook

7.4.4.1.         Market Size & Forecast

7.4.4.1.1.             By Value

7.4.4.2.         Market Share & Forecast

7.4.4.2.1.             By Clinical Trial Phase

7.4.4.2.2.             By Method

7.4.4.2.3.             By Service Provider

7.4.4.2.4.             By End-User

7.4.5.     Singapore Pharmacovigilance Market Outlook

7.4.5.1.         Market Size & Forecast

7.4.5.1.1.             By Value

7.4.5.2.         Market Share & Forecast

7.4.5.2.1.             By Clinical Trial Phase

7.4.5.2.2.             By Method

7.4.5.2.3.             By Service Provider

7.4.5.2.4.             By End-User

7.4.6.     Australia Pharmacovigilance Market Outlook

7.4.6.1.         Market Size & Forecast

7.4.6.1.1.             By Value

7.4.6.2.         Market Share & Forecast

7.4.6.2.1.             By Clinical Trial Phase

7.4.6.2.2.             By Method

7.4.6.2.3.             By Service Provider

7.4.6.2.4.             By End-User

8.    Europe Pharmacovigilance Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Clinical Trial Phase

8.2.2.     By Method

8.2.3.     By Service Provider

8.2.4.     By End-User

8.2.5.     By Country

8.3.  Market Attractiveness Index

8.4.  Europe: Country Analysis

8.4.1.     France Pharmacovigilance Market Outlook

8.4.1.1.         Market Size & Forecast

8.4.1.1.1.             By Value

8.4.1.2.         Market Share & Forecast

8.4.1.2.1.             By Clinical Trial Phase

8.4.1.2.2.             By Method

8.4.1.2.3.             By Service Provider

8.4.1.2.4.             By End-User

8.4.2.     Germany Pharmacovigilance Market Outlook

8.4.2.1.         Market Size & Forecast

8.4.2.1.1.             By Value

8.4.2.2.         Market Share & Forecast

8.4.2.2.1.             By Clinical Trial Phase

8.4.2.2.2.             By Method

8.4.2.2.3.             By Service Provider

8.4.2.2.4.             By End-User

8.4.3.     United Kingdom Pharmacovigilance Market Outlook

8.4.3.1.         Market Size & Forecast

8.4.3.1.1.             By Value

8.4.3.2.         Market Share & Forecast

8.4.3.2.1.             By Clinical Trial Phase

8.4.3.2.2.             By Method

8.4.3.2.3.             By Service Provider

8.4.3.2.4.             By End-User

8.4.4.     Italy Pharmacovigilance Market Outlook

8.4.4.1.         Market Size & Forecast

8.4.4.1.1.             By Value

8.4.4.2.         Market Share & Forecast

8.4.4.2.1.             By Clinical Trial Phase

8.4.4.2.2.             By Method

8.4.4.2.3.             By Service Provider

8.4.4.2.4.             By End-User

8.4.5.     Russia Pharmacovigilance Market Outlook

8.4.5.1.         Market Size & Forecast

8.4.5.1.1.             By Value

8.4.5.2.         Market Share & Forecast

8.4.5.2.1.             By Clinical Trial Phase

8.4.5.2.2.             By Method

8.4.5.2.3.             By Service Provider

8.4.5.2.4.             By End-User

8.4.6.     Spain Pharmacovigilance Market Outlook

8.4.6.1.         Market Size & Forecast

8.4.6.1.1.             By Value

8.4.6.2.         Market Share & Forecast

8.4.6.2.1.             By Clinical Trial Phase

8.4.6.2.2.             By Method

8.4.6.2.3.             By Service Provider

8.4.6.2.4.             By End-User

9.    North America Pharmacovigilance Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Clinical Trial Phase

9.2.2.     By Method

9.2.3.     By Service Provider

9.2.4.     By End-User

9.2.5.     By Country

9.3.  Market Attractiveness Index

9.4.  North America: Country Analysis

9.4.1.     United States Pharmacovigilance Market Outlook

9.4.1.1.         Market Size & Forecast

9.4.1.1.1.             By Value

9.4.1.2.         Market Share & Forecast

9.4.1.2.1.             By Clinical Trial Phase

9.4.1.2.2.             By Method

9.4.1.2.3.             By Service Provider

9.4.1.2.4.             By End-User

9.4.2.     Mexico Pharmacovigilance Market Outlook

9.4.2.1.         Market Size & Forecast

9.4.2.1.1.             By Value

9.4.2.2.         Market Share & Forecast

9.4.2.2.1.             By Clinical Trial Phase

9.4.2.2.2.             By Method

9.4.2.2.3.             By Service Provider

9.4.2.2.4.             By End-User

9.4.3.     Canada Pharmacovigilance Market Outlook

9.4.3.1.         Market Size & Forecast

9.4.3.1.1.             By Value

9.4.3.2.         Market Share & Forecast

9.4.3.2.1.             By Clinical Trial Phase

9.4.3.2.2.             By Method

9.4.3.2.3.             By Service Provider

9.4.3.2.4.             By End-User

10.  South America Pharmacovigilance Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Clinical Trial Phase

10.2.2.  By Method

10.2.3.  By Service Provider

10.2.4.  By End-User

10.2.5.  By Country

10.3.              Market Attractiveness Index

10.4.              South America: Country Analysis

10.4.1.  Brazil Pharmacovigilance Market Outlook

10.4.1.1.      Market Size & Forecast

10.4.1.1.1.           By Value

10.4.1.2.      Market Share & Forecast

10.4.1.2.1.           By Clinical Trial Phase

10.4.1.2.2.           By Method

10.4.1.2.3.           By Service Provider

10.4.1.2.4.           By End-User

10.4.2.  Argentina Pharmacovigilance Market Outlook

10.4.2.1.      Market Size & Forecast

10.4.2.1.1.           By Value

10.4.2.2.      Market Share & Forecast

10.4.2.2.1.           By Clinical Trial Phase

10.4.2.2.2.           By Method

10.4.2.2.3.           By Service Provider

10.4.2.2.4.           By End-User

10.4.3.  Colombia Pharmacovigilance Market Outlook

10.4.3.1.      Market Size & Forecast

10.4.3.1.1.           By Value

10.4.3.2.      Market Share & Forecast

10.4.3.2.1.           By Clinical Trial Phase

10.4.3.2.2.           By Method

10.4.3.2.3.           By Service Provider

10.4.3.2.4.           By End-User

11.  Middle East and Africa Pharmacovigilance Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Clinical Trial Phase

11.2.2.  By Method

11.2.3.  By Service Provider

11.2.4.  By End-User

11.2.5.  By Country

11.3.              Market Attractiveness Index

11.4.              MEA: Country Analysis

11.4.1.  South Africa Pharmacovigilance Market Outlook

11.4.1.1.      Market Size & Forecast

11.4.1.1.1.           By Value

11.4.1.2.      Market Share & Forecast

11.4.1.2.1.           By Clinical Trial Phase

11.4.1.2.2.           By Method

11.4.1.2.3.           By Service Provider

11.4.1.2.4.           By End-User

11.4.2.  Saudi Arabia Pharmacovigilance Market Outlook

11.4.2.1.      Market Size & Forecast

11.4.2.1.1.           By Value

11.4.2.2.      Market Share & Forecast

11.4.2.2.1.           By Clinical Trial Phase

11.4.2.2.2.           By Method

11.4.2.2.3.           By Service Provider

11.4.2.2.4.           By End-User

11.4.3.  UAE Pharmacovigilance Market Outlook

11.4.3.1.      Market Size & Forecast

11.4.3.1.1.           By Value

11.4.3.2.      Market Share & Forecast

11.4.3.2.1.           By Clinical Trial Phase

11.4.3.2.2.           By Method

11.4.3.2.3.           By Service Provider

11.4.3.2.4.           By End-User

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              Competition Outlook

14.2.              Players Profiled (Leading Companies)

14.2.1.  F. Hoffmann-La Roche

14.2.2.  Accenture

14.2.3.  Cognizant

14.2.4.  Laboratory Corporation of America Holdings

14.2.5.  IBM Corporation

14.2.6.  ArisGlobal

14.2.7.  Foresight Group International AG

14.2.8.  ICON PLC

14.2.9.  Capgemini

14.2.10.                United BioSource Corporation

14.2.11.                Wipro Ltd

14.2.12.                BioClinica

14.2.13.                Bristol-Myers Squibb

14.2.14.                Clinquest Group

14.2.15.                Novartis International

14.2.16.                GlaxoSmithKlin

14.2.17.                PAREXEL International

14.2.18.                iGATE Corporation

14.2.19.                iMEDGlobal Corporation

14.2.20.                inVentiv Health

15.  Strategic Recommendations

16. About Us & Disclaimer